Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
SenesTech, Inc. is a biotechnology company focused on the development and commercialization of non-lethal pest control solutions, specifically targeting rodent populations through fertility control. The company operates at the intersection of biotechnology, pest management, and animal health, with a mission to provide environmentally responsible alternatives to traditional rodenticides. Its core product is designed to reduce rodent populations by limiting reproduction rather than causing direct mortality, positioning the company within the growing market for sustainable pest control solutions.
The company’s primary revenue driver is its proprietary liquid fertility control product, sold under the brand ContraPest®, which is formulated to reduce fertility in both male and female rats. SenesTech serves municipal governments, commercial pest control operators, agricultural customers, and public health agencies. The company was founded in 2004 and went public in 2016. Its evolution reflects a shift from early-stage research and regulatory validation toward commercialization and market expansion in urban and agricultural settings.
Business Operations
SenesTech operates as a single-reportable-segment company focused on rodent fertility control, with revenues generated primarily from sales of ContraPest® and related delivery systems. The product is manufactured and distributed for use in both commercial and municipal pest management programs. Operations include product manufacturing oversight, regulatory compliance, sales and marketing, and ongoing research and development to enhance formulations and delivery mechanisms.
The company’s operations are primarily based in the United States, with limited international sales and distribution partnerships. SenesTech controls proprietary formulations, intellectual property related to fertility control compounds, and specialized bait delivery technologies. Data on significant joint ventures or large-scale subsidiaries is inconclusive based on available public sources, and the company appears to operate largely through its parent corporate structure without material operating subsidiaries.
Strategic Position & Investments
SenesTech’s strategic direction centers on expanding adoption of fertility control as a mainstream rodent management strategy. Growth initiatives include increasing penetration in large urban municipalities, expanding relationships with national and regional pest control operators, and pursuing additional regulatory approvals that broaden allowable use cases for its products. The company has emphasized recurring-use models tied to long-term rodent management programs rather than one-time product sales.
Investment activity has primarily focused on internal research and development, regulatory compliance, and commercialization infrastructure rather than large acquisitions. No major acquisitions have been consistently identified across public filings and independent financial reporting. The company is also engaged in advancing fertility control technologies as an emerging segment within pest management, positioning itself as a differentiated provider relative to traditional chemical rodenticides.
Geographic Footprint
SenesTech is headquartered in Arizona, United States, and its core operations, sales activities, and regulatory approvals are primarily U.S.-based. The company’s products are deployed in multiple U.S. urban and agricultural markets, including large metropolitan areas where rodent control is a public health priority.
Internationally, SenesTech has pursued selective market entry through distribution arrangements and regulatory efforts, including limited activity in parts of Europe, Asia, and other regions. However, the majority of revenue and operational influence remains concentrated in North America, and international operations currently represent a smaller portion of overall business activity.
Leadership & Governance
SenesTech is led by an executive team with experience in biotechnology commercialization, pest management, and public company governance. Leadership has emphasized regulatory credibility, scientific validation, and long-term market education as core elements of the company’s strategic vision.
Key executives include:
- Joel Fruendt – Chief Executive Officer
- Christine M. MacKay – Chief Financial Officer
- Bruce DeMuth – Chief Scientific Officer
- Susan M. Pauly – Vice President, Operations
Information regarding founders and certain historical executive roles varies across disclosures; some details are inconclusive based on available public sources. The board of directors provides oversight consistent with U.S. public company governance standards, with an emphasis on regulatory compliance and strategic risk management.